Modern Slavery and Human
Trafficking Statement
Our Commitment to Ethical Business Practices
Synergy Biologics Limited is committed to operating responsibly and opposing all forms of modern slavery and human trafficking.
​
As a UK manufacturer, distributor and retailer of nutraceutical and healthcare products, we work with approved suppliers who are assessed against quality, regulatory and ethical standards. Although we are below the reporting threshold under the Modern Slavery Act 2015, we voluntarily publish this statement as part of our commitment to transparency and responsible business practices.
​
Our MHRA WDA(H) and MIA licences further support robust governance, quality assurance and supply chain oversight across our operations.
Supporting and Protecting Our Employees
We provide employees with guidance on recognising and reporting concerns relating to modern slavery and human trafficking, both within the workplace and wider community.
​
Our Modern Slavery Statement forms part of employee onboarding and internal policies, with confidential whistleblowing and reporting procedures available to all team members.
Responsible Supply Chain Oversight
We apply due diligence procedures across our supply chain to help identify and reduce potential risks.
​
Supplier approval questionnaires, audits and ongoing assessments are used to review areas including labour standards, safety, legal compliance, environmental responsibility and ethical sourcing. This helps ensure suppliers align with our operational and ethical expectations.
Ongoing Review and Accountability
We remain committed to monitoring and improving our practices to help prevent modern slavery and human trafficking throughout our operations and supply chain.
​
This statement is reviewed annually and updated where appropriate to reflect operational changes, evolving risks and legislative developments.
​
This statement has been approved by the Board of Directors of Synergy Biologics Limited in accordance with Section 54(6) of the Modern Slavery Act 2015. [September 2025]
​​​​​​​
​​
Robin Deb
Managing Director
